Analgesic nephropathy future or investigational therapies
|
Analgesic nephropathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Analgesic nephropathy future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Analgesic nephropathy future or investigational therapies |
|
FDA on Analgesic nephropathy future or investigational therapies |
|
CDC on Analgesic nephropathy future or investigational therapies |
|
Analgesic nephropathy future or investigational therapies in the news |
|
Blogs on Analgesic nephropathy future or investigational therapies |
|
Risk calculators and risk factors for Analgesic nephropathy future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Further randomized trials are required to assess the incidence of renal injury and analgesic nephropathy caused by certain drugs.
Future or Investigational Therapies
Further randomized trials are required to assess the incidence of renal injury and analgesic nephropathy caused by certain drugs.[1]
References
- ↑ Yaxley J (2016). "Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence". Int J Risk Saf Med. 28 (4): 189–196. doi:10.3233/JRS-170735. PMID 28582877.